Development Pipeline

From Concept to Clinic

TVC001 Pancreatic Cancer TVC002 Bladder Cancer

These live attenuated bacterial vectors are engineered to deliver tumor-specific antigens directly to the tumor microenvironment.

TVC001 � Pancreatic Cancer

TVC001 is our lead candidate targeting pancreatic ductal adenocarcinoma (PDAC). It uses a Salmonella-based vector to deliver tumor-specific neoantigens and immunostimulants such as IL-12 or ClyA-FliC into the tumor microenvironment.

Promoters: tumor- and hypoxia-specific (e.g., pagC, nirB)
Antigen delivery: SPI-1/SPI-2 secretion systems
Preclinical models: Orthotopic PDAC in mice
Goal: IND submission for Phase 1 trial in 2026

TVC002 � Bladder Cancer

TVC002 is under development for intravesical treatment of bladder cancer (non-muscle invasive and recurrent). The bacterial vector is optimized for localized delivery and immune activation in the bladder wall.

Delivery: Intravesical instillation
Target antigens: PRAME, Survivin, and mutation-derived neoepitopes
Adjuvants: ClyA-FliC fusion proteins, GM-CSF
Preclinical validation ongoing (urothelial cancer models)

Our R&D Pipeline

Discovery Phase
Identification of tumor-specific antigens and optimal bacterial delivery mechanisms.
Preclinical Validation
Testing in murine pancreatic cancer models; safety, colonization, and immunogenicity.
Optimization
Engineering of vector strains with refined promoters, effectors, and immunostimulants (e.g., IL-12, ClyA-FliC).
Regulatory & GMP Readiness
Preparing for IND-enabling studies and early-phase GMP manufacturing.
First-in-Human Trials
Phase 1 clinical testing in selected PDAC patients, focusing on safety and immunologic efficacy.

Each step is guided by rigorous scientific evaluation and partnership with academic and clinical institutions.